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Change in Function, Pain and Quality of Life following Structured Nonoperative 
Treatment in Patients with Degenerative Cervical Myelopathy: A Systematic 
Review  
 
Lindsay Tetreault*, Mohammed F Shamji*, John Rhee, Heidi Prather, Brian K. Kwon, Jeff Wilson, 
Ian B. Andersson, Anna H. Dembek, Krystle T. Pagarigan, Joseph R. Dettori, Michael G. Fehlings  
 
Abstract  
Study Design. Systematic review.  
Objective. To conduct a systematic review of the literature to determine (1) the change in 
function, pain and quality of life following structured nonoperative treatment for degenerative 
cervical myelopathy (DCM); (2) the variability of change in function, pain and quality of life  
following different types of structured nonoperative treatment; (3) the differences in outcomes 
observed between certain subgroups (i.e., baseline severity score, duration of symptoms); and 
(4) negative outcomes and harms resulting from structured nonoperative treatment.  
Summary of Background Data. The role of structured nonoperative treatment for the 
management of DCM is not well defined, and surgery is typically recommended as the default 
treatment option for patients with moderate and severe myelopathy.    
Methods. A systematic search was conducted in Embase, PubMed, and the Cochrane 
Collaboration for articles published between January 1, 1950 and February 9, 2015. Studies 
were included if they evaluated outcomes following structured nonoperative treatment, 
including therapeutic exercise, manual therapy, cervical bracing and/or traction. Outcomes of 
interest were functional status (Japanese Orthopedic Association (JOA), Nurick), pain in upper 
extremities and neck, quality of life (Neck Disability Index), and/or conversion to surgery. The 
quality of each study was evaluated using the Newcaste-Ottawa Scale and the strength of the 
Page 2 of 35 
 
overall body of evidence was rated using guidelines outlined by the Grading of 
Recommendation Assessment, Development and Evaluation Working Group (GRADE). 
Results. Of the 570 retrieved citations, eight met the inclusion criteria and were included in this 
review. There is very low evidence to suggest that structured nonoperative treatment for DCM 
results in a positive or negative change in function, pain and quality of life as evaluated by the 
JOA score. There is also limited evidence from three studies indicating that early structured 
nonoperative treatment (duration of symptoms <1 year) may be associated with positive 
clinical outcomes. There were no studies that directly compared structured nonoperative 
treatment types and no studies that explored outcomes based on patient subgroups. The rate 
of conversion to surgery was reported to be between 23-54%. 
Conclusion. There is a lack of evidence to determine the role of nonoperative treatment in 
patients with DCM. However, in the majority of studies, patients did not achieve clinically 
significant gains in functional status following structured nonoperative treatment. Furthermore, 
23-54% of patients subsequently underwent surgical treatment.  
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INTRODUCTION   
 Degenerative cervical myelopathy (DCM) is a progressive spine disease and the most 
common cause of spinal cord dysfunction in adults worldwide.1,2 It is caused by age-related 
alterations to the spinal axis, including degeneration of the facet joints, intervertebral discs 
and/or vertebral bodies; progressive spinal kyphosis; and/or ligamentous aberrations including 
ossification, calcification and hypertrophy of the spinal ligaments.3 These anatomical changes 
lead to the narrowing of the spinal canal and may result in progressive cord compression, 
neurological deterioration and significantly reduced quality of life.  
Early reports on the natural history have defined DCM as a relatively “benign” conditioj 
in which patients are often stable for long periods of time following symptom onset.4,5 
However, there is increasing evidence to suggest that DCM is a progressive disorder and that 
myelopathic individuals may experience a gradual stepwise decline in neurological status.6 A 
recent systematic review of the literature reported that 20-60% of patients with symptoms of 
myelopathy deteriorate by at least one point on the Japanese Orthopedic Association score 
(JOA) three to six years after initial assessment.7 It is therefore important to recognize early 
signs and symptoms of myelopathy in order to implement appropriate treatment strategies to 
minimize functional loss related to pain and neurological impairment.  
Surgery has become increasingly recommended as a “first-line” treatment for patients 
with DCM, as decompression not only effectively halts disease progression but also results in 
significant gains in functional status and quality of life.8-12 In contrast, the effectiveness of 
structured nonoperative treatment in stabilizing or improving DCM symptoms is not well 
defined, making it difficult to determine the appropriate role of nonoperative treatment in the 
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management of DCM, particularly in individuals with mild symptoms.  As such, the objective of 
this study is to conduct a systematic review of the literature to address four clinical questions: 
In adult patients with DCM,  
(1) What is the change in function, pain and quality of life following nonoperative treatment?   
(2) Does this change in function, pain and quality of life vary depending on type of nonoperative 
treatment? 
(3) Does the change in function, pain and quality of life following nonoperative care differ 
across subgroups (e.g., myelopathy severity or duration of myelopathy symptoms)?   
(4) What are the harms of nonoperative care and what is the percentage of patients who 
subsequently undergo surgery? 
 
MATERIALS AND METHODS 
Electronic Literature Search 
We conducted a systematic search in Embase, PubMed, and the Cochrane Collaboration 
Library for literature published between January 1, 1950 and February 9, 2015 to identify 
studies that reported the outcomes of structured nonoperative treatment for the management 
of DCM. “Structured nonoperative treatment” was defined as any non-surgical intervention and 
included therapeutic exercise, manual therapy, bracing, cervical traction and others. Our search 
was limited to human studies published in English. Reference lists from the articles produced by 
the search were reviewed manually to identify additional publications. For clinical questions 1 
through 4, we included studies that reported changes in function, pain and/or health-related 
quality of life following structured non-operative treatment in adult patients (≥18 years of age) 
diagnosed with DCM due to spondylosis, herniated discs, and/or ossification of the posterior 
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longitudinal ligament (OPLL). We also included studies which reported the percentage of 
patients who ultimately were treated surgically following a period of structured nonoperative 
treatment, as well as studies that stratified subjects based on baseline myelopathy severity.  
For clinical question 2, we sought to identify studies that explored competing nonoperative 
interventions for the management of DCM.  
Studies were excluded if they (1) included subjects under 18 years of age or patients 
with myelopathy due to infection, malignancy, acute injury including acute disc herniation, 
inflammatory arthritis, or trauma; (2) only reported outcomes following surgical intervention; 
(3) did not state what type of structured nonoperative treatment was performed; (4) did not 
evaluate outcome using at least one primary outcome measure (JOA, Nurick, conversion to 
surgery following nonoperative treatment); (5) reported on fewer than 10 subjects; and/or (6) 
were related to animals or cadavers, or were strictly biomechanical evaluations. Full inclusion 
and exclusion criteria are provided in Table 1. Two investigators (AHD, IBA) independently 
reviewed the full texts of potential articles and excluded all studies that did not meet the 
inclusion criteria, Figure 1.  Selection discrepancies were settled through discussion.  
Data Extraction 
The following data were extracted from each included article: study design; patient 
characteristics, including mean age, baseline severity score and type of DCM; length and rate of 
follow-up; type and duration of nonoperative treatment; outcomes assessed; and associations 
between nonoperative interventions and outcomes (function, pain, quality of life and/or 
conversion to surgery). We attempted to identify studies with overlapping data to prevent 
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double-counting. In such cases, we selected the study with the most complete data, largest 
sample size and greatest follow-up period.  
Study Quality and Overall Strength of Body of Literature  
Each article was appraised for risk of bias by two reviewers (KTP, JRD) using the 
modified Newcastle-Ottawa Scale (NOS).13  Strength of the overall body of evidence for each 
outcome was determined by guidelines outlined by the Grading of Recommendation 
Assessment, Development and Evaluation Working Group (GRADE).14,15 Though the GRADE 
scale is intended to rate the quality of evidence and strength of recommendation of 
comparative studies, we adapted the principles for this systematic review to determine the 
confidence we have in the magnitude of the effect in the change in function, pain, and quality 
of life from nonoperative treatment.  
The overall body of evidence is considered LOW if all studies are observational. The 
quality of the body of evidence may be upgraded or downgraded depending upon a number of 
factors. Criteria for downgrading published evidence one or two levels include (1) inconsistency 
of results, (2) indirectness of evidence, or (3) imprecision of the effect estimates (e.g., wide 
variance). Alternately, the body of evidence could be upgraded 1 or 2 levels based on (1) large 
magnitude of effect or (2) dose-response gradient.  
A quality level of HIGH indicates high confidence that the true effect lies close to that of 
the estimate of effect. A MODERATE quality level reflects moderate confidence in the effect 
estimate; the true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different. A LOW quality estimate represents limited 
confidence in the effect estimate, and that the true effect may be substantially different from 
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the estimate of the effect.15 VERY LOW ratings indicate very little confidence in the effect 
estimate; the true effect is likely to be substantially different from the estimate of effect. This 
rating may be used if there is no evidence or if it is not possible to estimate an effect. 
Data Analysis  
For clinical questions 1, 2 and 3, changes in JOA or modified JOA (mJOA) scores before 
(at baseline) and after structured nonoperative treatment were reported and summarized. The 
minimal clinically important difference (MCID) for the JOA has not been established; however, 
expert opinion indicates a score change ≥2.0 points is considered clinically significant.16,17 
Furthermore, the MCID of the mJOA has been estimated to be between 1 and 2 points.18 For 
clinical question 4, a summary table was used to identify the proportion of subjects that 
received surgical intervention after a period of structured nonoperative treatment.  
RESULTS 
Study Selection 
Our initial search yielded 570 citations. Following title, abstract, and full-text review, we 
identified eight studies that met our inclusion criteria for clinical questions 1, 2, and 3, Figure 1 
and Table 2. Five of these studies also addressed clinical question 4 and reported proportions of 
subjects that subsequently underwent surgical intervention after a period of structured 
nonoperative treatment. Of the remaining 562 studies, 541 were excluded at title and abstract 
level as they primarily focused on surgical intervention and did not appropriately evaluate 
outcome following structured nonoperative treatment. After full-text review, 20 additional 
studies were excluded for the following reasons: inappropriate study design (n = 5), inclusion of 
patients with trauma or radiculopathy (n = 3), abstract publication only (n = 2), inappropriate 
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outcome measures (n = 2), duplicate data (n = 2), surgical treatment only (n = 1), non-cervical 
condition (n = 1), non-English publication (n = 1), and no description of structured nonoperative 
intervention (n = 2). A list of excluded studies and full data abstraction tables can be found in 
the supplemental electronic material. 
Summary of Studies and Risk of Bias  
 Types of structured nonoperative treatment varied across studies and were not well-
defined. Treatments included bed rest, cervical traction, cervical immobilization or bracing 
thermal therapy, physical therapy and/or non-steroidal anti-inflammatory drugs. Outcomes 
were assessed using a variety of measures such as the JOA, timed 10-meter walking test, Neck 
Disability Index (NDI) and Activities of Daily Living (ADL). Some studies also reported rates of 
conversion to surgery following an initial trial of conservative management. 
 Based on the modified NOS, six studies had “moderately low risk of bias” and two were 
rated as “moderately high risk of bias.” Significant methodological flaws included high attrition 
rate (n = 4), selection bias in choosing source population (n = 1) and small sample sizes (n = 3). A 
detailed critical appraisal of each study can be found in the Supplemental Electronic Material.  
What is the change in function, pain and quality of life following structured nonoperative 
treatment for degenerative cervical myelopathy? 
Assessment of JOA or mJOA scores 
Six studies reported outcomes following structured nonoperative treatment using 
change in JOA (n = 5) or mJOA (n = 1) scores from baseline to follow-up, Table 3. Sample sizes 
ranged from 32 to 90 subjects, with mean baseline severity scores from 11.1 to 14.6 on the 
JOA/mJOA. Response to treatment was minimal, with change scores ranging from 0 to 2.3.  
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Only a single study by Matsumoto et al19 reported a mean JOA change score ≥2.0 points at final 
follow-up (mean: 47 months). 
Two additional studies evaluated outcomes using the JOA but did not report change 
scores. A retrospective cohort study by Nakamura et al20 evaluated changes in motor function 
of the upper and lower extremities following a variety of structured nonoperative treatments: 
continuous head-halter traction (n = 2), cervical bracing (n = 19), plaster bed immobility (n = 15) 
or Crutchfield’s skull traction (n = 28). Extremity function was assessed in sixty-four subjects 
(74% male, mean age: 54 years) using a disability scale from 0 (“severe impairment”) to 4 (“no 
disability”) based on JOA scores. At final follow-up (mean: 47 months), 27% (15/56) and 26% 
(16/61) of patients who received structured nonoperative treatment had “no disability” in the 
upper and lower extremities, respectively.  
In a second retrospective study, Yoshimatsu et al21 investigated symptomatic changes in 
69 patients with DCM who elected not to undergo surgery immediately following diagnosis. 
Myelopathy severity and functional disability were assessed at baseline using the JOA. Of the 69 
subjects, 12 refused treatment, 37 underwent “rigorous” nonoperative care, and 20 received 
non-rigorous care. “Rigorous” treatment consisted of 3 to 4 hours of continuous cervical 
traction per day for 1-3 months, combined with immobilization by cervical orthosis, exercise 
therapy, drug therapy, and thermal therapy. A description of non-rigorous intervention was not 
provided. To evaluate treatment effects, baseline and post-treatment JOA scores were 
compared and subjects were classified into three groups based on whether they exhibited 
“improvement”, “no change”, or “exacerbation of symptoms” at final follow-up (mean: 29 
months). Twenty-six percent (15/57) of patients who received structured nonoperative 
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treatment demonstrated improvements of JOA scores between baseline and follow-up, and 
only 8% (1/12) of patients who refused structured nonoperative care exhibited gains. In 
addition, a smaller percentage of patients who received structured nonoperative care 
experienced “exacerbation of symptoms” based on the JOA (58%; 33/57) than those who 
refused nonoperative treatment (83%; 10/12). However, the difference between patients 
receiving structured nonoperative care and those refusing treatment with respect to JOA 
improvements and exacerbation of symptoms was within the limits of chance. 
Does the change in function, pain and quality of life vary depending on treatment type?           
No studies directly compared outcomes between different structured nonoperative 
treatment strategies; however, one study evaluated outcomes based on different treatment 
“intensities.” A retrospective cohort study by Yoshimatsu et al21 investigated symptomatic 
changes in 69 patients with DCM who received either rigorous or nonrigorous nonoperative 
treatment. Thirty-eight percent (14/37) of patients receiving rigorous nonoperative treatment 
reported some improvement, compared with only 6% (2/32) of patients reporting improvement 
after receiving non-rigorous nonoperative treatment. The proportion of patients with 
worsening of symptoms was 49% (18/37) and 78% (25/32), respectively.  
Does the change in function, pain and quality of life with nonoperative care vary according to 
subgroups (i.e., myelopathy severity or duration of symptoms)?  
Duration of Symptoms  
Three studies evaluated the correlation between duration of symptoms prior to 
structured nonoperative treatment and post-treatment JOA scores.20,22 Fukui et al22 evaluated 
changes in functional disability on the JOA score following 2 weeks of cervical traction. 
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Pretreatment JOA scores for 53 subjects ranged from 6 to 15 with a mean of 11.1 points (3 
subjects refused structured nonoperative treatment, n = 50). Fifty-six percent (28/50) of 
subjects demonstrated post-treatment JOA improvements. In patients with a duration of 
symptoms less than three months, 80% (12/15) improved by at least one point on the JOA; in 
contrast, only 46% (16/35) with a duration of symptoms greater than three months exhibited 
≥1 point JOA improvement, risk ratio 1.75 (95% CI 1.13 to 2.72). Nakamura et al20 also 
evaluated whether duration of symptoms is predictive of JOA improvements following 
structured nonoperative treatment. For subjects with a duration less than 6 months, 30% (3/10) 
had “no disability” in the upper extremity and 36% (5/14) had “no disability” in the lower 
extremity following treatment. For subjects with a symptom duration >6 months, a slightly 
smaller percentage of patients achieved “no disability” in the upper (26%; 12/46) and lower 
(23%; 11/47) extremities. Although these differences were not statistically significant, the 
authors indicated that early intervention could result in improved treatment effects following 
structured nonoperative treatment.  
In a retrospective study, Li et al23 reported a significant correlation between JOA 
recovery ratios and disease durations (R=0.888, P<0.01) for a combined surgical and 
nonoperative group. Patients with a shorter duration of symptoms achieved superior clinical 
outcomes.  
Baseline Severity Score 
 No studies stratified their sample based on preoperative myelopathy severity. 
Other Subgroups 
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A retrospective cohort study by Matsumoto et al19 evaluated structured nonoperative 
treatment in patients with myelopathy secondary to cervical soft disc herniation. This study 
analyzed data from 27 subjects with moderate myelopathy (mean baseline JOA 13.8) who 
underwent cervical bracing, traction, and NSAID therapy for 6 months with a mean follow-up 
time of 3.9 years. Sixty-three percent (17/27) of patients demonstrated improvement or 
stability on the JOA at final follow-up and 59% (10/17) displayed spontaneous regression of 
their disc herniation and reduction in myelopathy symptoms. The authors concluded that 
structured nonoperative treatment may reduce neurological symptoms in patients with 
myelopathy secondary to cervical disc herniation.   
What are the harms of nonoperative care and what is the percent of patients who convert to 
surgery? 
No studies reported direct harms resulting from structured nonoperative treatment. Based on 
five studies, the proportion of subjects who underwent surgical intervention following a period 
of structured nonoperative treatment ranged from 23% to 54% (mean follow-up: 27 to 74 
months), Table 4. In patients with baseline JOA scores ≥13.0, 23% to 38% of patients ultimately 
received surgery. In patients with more severe myelopathy (JOA<13.0 (11.1)), Fukui et al22 
reported a rate of conversion of 54% (27/50) following a period of structured nonoperative 
treatment. Nakamura et al20 did not specify baseline JOA scores, but did indicate that 30% 
(19/64) eventually received surgical intervention at a follow up period ranging from 36 to 129 
months.  
 Evidence summary 
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Eight small studies, ranging in size from 27 to 90 patients, evaluated outcomes following 
structured nonoperative treatment in patients presenting with mostly mild to moderate DCM 
(mean baseline mJOA/JOA score ≥12). mJOA or JOA improvement from baseline was generally 
below the MCID with mean change scores ranging from 0 to 1 in most studies. One subgroup of 
patients with DCM resulting from soft disc herniation reported 63% (17/27) of patients with 
improved JOA scores at an average 4 year follow-up. The proportion of patients receiving 
surgery following nonoperative care ranged from 23% to 54% across five small studies. The 
quality of evidence for these findings is VERY LOW.   
 
DISCUSSION 
  
 There is increasing evidence to support that surgery results in significant and 
clinically meaningful improvements in functional status and quality of life in patients with 
varying degrees of myelopathy severity.8-12 On the other hand, the role of nonoperative 
treatment in these patients has not been well defined. It was therefore the objective of this 
review to evaluate changes in function, pain and quality of life outcomes in patients undergoing 
structured nonoperative treatment for DCM.  
 We found a lack of evidence to determine the appropriate role of nonoperative 
treatment in patients with DCM. Furthermore, based on the included studies in this review, the 
baseline mJOA or JOA either stayed the same or slightly improved following structured 
nonoperative treatment (0 to 2.3 points). However, there is very low evidence to suggest that 
these patients exhibit clinically meaningful gains in functional status. In this regard, it is 
important to consider patient choice as some patients may be satisfied with simply maintaining 
their level of function whereas others may seek surgical consultation. Furthermore, some 
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patients may not be ideal surgical candidates due to advanced age or multiple medical co-
morbidities.  
 Interestingly, the greatest reported improvements with nonoperative care occurred 
in studies involving patients with myelopathy due to soft disc herniation (Matsumoto, diff 2.3) 
and dynamic cervical myelopathy (Fukui, diff 1.7). These etiologies might be expected a priori to 
respond better to nonoperative care, since soft disc herniations may spontaneously regress, 
and immobilization may at least temporarily decrease cord irritation if the primary mechanism 
of compression is dynamic rather than static. In contrast, nonoperative treatment had less 
effect in studies involving DCM due to static spinal cord compression, or etiologies which do not 
tend to regress spontaneously over time (Table 3; difference in mJOA/JOA for these studies was 
0 to 1.1). Therefore, nonoperative care, based on the evidence in this review, may be reserved 
for milder myelopathy associated with soft disc herniations or dynamic stenosis. 
 This review also reported that 23% to 54% of patients converted to surgery following 
an initial period of conservative treatment. Given this wide range, it is important to predict 
which patients are at a high risk for disease progression and those who are most likely to 
eventually undergo surgical intervention. Important predictors of neurological deterioration 
and failed nonoperative treatment include (1) circumferential cord compression on an axial 
magnetic resonance image;24 (2) an “angular-edged” spinal cord, defined as an acute angled or 
lateral corner at one or both sides;25 (3) greater range of preoperative neck and head motion;26 
(4) lower segmental lordotic angle and greater percentage of vertebral slip;27 and (5) segmental 
instability and reduced diameter of the cerebrospinal fluid column.28  For patients who are in 
these high-risk groups, early surgery may be considered regardless of their myelopathy severity. 
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This is especially critical given recent reports that a longer duration of preoperative symptoms 
is predictive of a worse surgical outcome.29,30  
 
 Results of nonoperative management need to be separately evaluated in patients 
with varying myelopathy severities to better define its role. In a systematic review by Rhee et al 
(2013), the comparative effectiveness of surgery versus nonoperative management was 
explored.31 This review reported that there is little evidence to suggest that nonoperative 
treatment halts or reverses the progression of myelopathy and that nonoperative care should 
not be the primary treatment modality in patients with moderate to severe disease. Therefore, 
surgery should be considered in those with moderate to severe symptoms s without significant 
delay, as further disease progression could result in considerable harm, reduced quality of life, 
significant functional disability, and decreased responsiveness to surgery. In addition, Wu et al. 
found that myelopathic patients may be at a higher risk of sustaining a spinal cord injury or 
experiencing central cord syndrome following a fall, both of which are associated with not only 
individual neurologic but also societal economic burdens due to significant increased costs of 
management.32  
 There may be a potential role for nonoperative management in patients with milder 
and stable disease forms. Because no studies stratified their samples into cohorts based on 
preoperative severity, we are unable to determine whether patients with mild myelopathy 
(mJOA≥15) improve by the MCID on the mJOA/JOA following structured nonoperative 
treatment.  
Limitations  
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 Clinicians who treat myelopathic patients may ask the question “is it reasonable to 
prescribe an initial trial of nonoperative care for patients with DCM?” This systematic review 
reveals significant flaws in the literature and cannot provide a strong evidence-based answer to 
this question. The major limitation in the body of evidence is that the type of “structured 
nonoperative care” is often poorly defined and consists a myriad of treatments, including 
traction, bracing, massage, exercise and drug administration. The variability of treatment 
modalities across studies makes it challenging to derive conclusions regarding the effectiveness 
of nonoperative care for DCM. As seen in Table 5, the level of evidence for each question was 
deemed “VERY LOW,” reflecting little confidence that the estimation of the treatment effect 
matches the true effect. 
There are additional limitations in the body of the evidence. Studies included in this 
review poorly defined treatment parameters. For example, four studies reported that drug 
therapy was used as a method of structured nonoperative care.19,21,23,34 However, none of 
these studies defined the types of drugs, dosing instructions, or duration of use. Additionally, 
three studies used other forms of treatment including exercise, thermal therapy or physical 
therapy19,21,23 but did not provide further description of these treatments, whether they 
overlapped, how intensely they were administered, and how compliant individuals were.  As a 
result, we are unable to draw concrete conclusions about the superiority of various 
conservative treatment modalities over other strategies.   
Second, although most studies evaluated functional status using the JOA, one study 
used the mJOA, a scale developed to account for cultural differences between Eastern and 
Western societies.33,34 A recent study by Kato et al16 compared the original JOA with the mJOA 
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and determined that, although the two scales are highly correlated (Spearman’s rho = 0.87), it 
is not ideal to use them interchangeably. Consequently, the ability to generalize mJOA data 
with JOA data is limited. Furthermore, two studies used different methods to assess functional 
status that could not be fully compared to change in JOA or mJOA scores.  
 Third, the MCID of the mJOA has been shown to vary depending on myelopathy 
severity: 1 in mild patients (mJOA≥15), 2 in moderate patients (mJOA=12-14) and 3 in severe 
patients (mJOA<12).18 However, the studies included in this review did not stratify their sample 
based on preoperative severity scores. There may be a role for nonoperative treatment in mild 
patients (mJOA≥15) if they could demonstrate improvements on the mJOA by 1 or more points.  
 Finally, there is a wide range of follow-up duration among the included studies, which 
makes it difficult to discern changes due to intervention from changes due to natural disease 
progression.    
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Figure 1. Results of literature search  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Citations from electronic search             
(n =556) 
  
5. Full-text review                             
 (n = 29) 
7. Publications included                     
(n = 8) 
3. Total citations 
(n = 570) 
6. Excluded after full-text review  
(n = 20) 
2. Citations from hand search                              
(n=14) 
4. Excluded after title/abstract review 
(n = 541) 
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Table 1. PICO Table 
SF-36 indicates Short-Form 36; NDI: Neck Disability Index; VAS, Visual Analog Scale; JOA, Japanese 
Orthopedic Association; RCT, Randomized Controlled Trials
 Inclusion: Exclusion: 
Patient Clinical Questions 1-4: 
 Adult patients (≥ 18 years) with diagnosed 
myelopathy due to spondylosis, herniated 
disc, and/or ossification of the posterior 
longitudinal ligament. 
 Patients < 18 years of age 
 Myelopathy due to infection, 
malignancy, acute injury, 
inflammatory arthritis or trauma 
Intervention Clinical Questions 1-4: 
 Therapeutic exercise 
 Manual therapy 
 Bracing 
 Cervical traction 
 Other nonoperative treatments 
 Surgical intervention 
 
Comparison Clinical Question 2: 
 Competing non-operative intervention 
 
Outcomes Clinical Questions 1-4: 
 Quality of life (SF-36 NDI) 
 Pain (VAS)  
 Functional status (JOA, Nurick) 
 Follow-up interview (progression and 
management)  
 Conversion to surgery 
 
Study Design Clinical Question 2: 
 RCT 
 Cohort Studies   
Clinical Questions 1,3,4: 
 Case series  
 Case reports 
 Literature review 
 Narrative review 
 Animal studies 
 Studies with <10 patiets 
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Table 2. Characteristics of studies 
Author(Years) 
Study Design 
Patient 
Characteristics  
Condition, 
Severity, Duration 
Intervention Outcome 
measures 
Mean f/u 
(range) % f/u 
Risk of Bias 
Fukui et al (1990)22 
 
Prospective cohort 
 
N=50*  
Mean age: 58.6  
79% male 
 
Condition: DCM 2° 
to dynamic canal 
stenosis 
Baseline JOA: 11.1 
Mean Sx† duration: 
2 years, 11 
months; range, 1 
month to 10 years 
Continuous cervical traction  
2 weeks (n=50) 
JOA score 
Surgery  
2.5 yrs (range 
NR) 
%NR 
High Risk 
Kadanka et al (2002; 
2011)33,34 
 
RCT ‡  
N=35 
Mean age: 54 
74.3% male 
Condition: DCM 
Baseline mJOA: 
14.6  
Median Sx 
duration: 1 year; 
range, 0.3 to 6 
years 
Intermittent cervical bracing with 
soft collar (n=NR) 
NSAIDs (n=NR) 
Intermittent bed rest 2° to pain 
(n=NR) 
Modified JOA 
score  
Time 10-m 
walk  
ADL score  
Subjective  
assessment 
12 mos: NR  
24 mos: NR  
36 mos: 83% 
120 mos: 78%  
 
Moderately High 
Risk  
Kong et al (2013) 
 
Prospective cohort  
 
N=90  
Mean age: 57.8  
58% male 
Condition: DCM 
Baseline JOA: 14.2 
±1.0  
Mean Sx duration:  
20.3 months  
 
Continuous cervical traction  
8 hours/day for 2 weeks (Good-
Samaritan) (n=90) 
JOA score 
Surgery 
40 months 
(36-56 mos)  
87% 
Low Risk 
 
Li et al (2014)23 
 
Retrospective cohort  
 N=38§   
Mean age: 51.7  
52% male 
Condition: CSM  
Baseline JOA: 14.4  
Mean Sx duration: 
5.97±5.08 months 
Oral drugs (n=NR) 
Traction (n=NR) 
Acupuncture (n=NR) 
Physiotherapy (n=NR) 
Other conservative treatments 
(n=NR) 
 
JOA score 
NDI 
30.7 mos 
(range NR) 
% NR 
High Risk  
Matsumoto et al 
(2001)19 
 
Retrospective cohort 
N=27  
Mean age: 44.4 
74% male 
Condition: DCM 2° 
to Soft Disc 
Herniation 
Baseline JOA: 13.8 
±1.6 
Cervical bracing  
8 hours/day for 3 months (n=17) 
Physical therapy with intermittent 
cervical traction (n=4) 
NSAIDs (n=7) 
 
JOA 
Surgery 
3.9 yrs 
(1-7 yrs) 
%NR 
High Risk  
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Author(Years) 
Study Design 
Patient 
Characteristics  
Condition, 
Severity, Duration 
Intervention Outcome 
measures 
Mean f/u 
(range) % f/u 
Risk of Bias 
Mean Sx duration: 
4.7 months 
 
Nakamura et al 
(1998)20 
 
Retrospective cohort 
 
N=64 
Mean age: 52 
72% male 
Condition: DCM 
Baseline JOA: NR 
Mean Sx duration: 
24 months; range, 
1 month to 20 
years 
Continuous head halter traction 
(n=2)  
Cervical bracing (n=19) 
Plaster bed immobilization (n=15)  
Crutchfield skull traction (n=28) 
JOA 
Surgery 
74 mos  
(3-10 yrs)  
83%** 
Moderately High 
Risk  
 
Shimomura et al (2007) 
 
Prospective cohort 
 
N=70 
Mean age: 55.1 
54% male 
Condition: DCM 
Baseline JOA: 14.6 
±1.3  
Sx duration: NR 
Continuous cervical traction  
8 hours/day for 2 weeks (Good-
Samaritan) (n=70) 
 JOA  35.6 mos 
(10-60 mos)  
80% 
Moderately Low Risk  
Yoshimatsu et al 
(2001)21 
 
Retrospective cohort 
N=57†† 
Mean age: 67 
51% male 
Condition: DCM 
Baseline JOA: NR 
Mean Sx duration: 
28.5 months 
Continuous cervical traction  
3-4 hours/day for 1-3 months 
(Good-Samaritan) (n=NR) 
Immobilization (n=NR) 
Drug therapy (n=NR) 
Exercise therapy (n=NR) 
Thermal therapy (n=NR) 
JOA 
Surgery 
29 mos 
(1-76 mos) 
NR 
Moderately High 
Risk  
f/u, follow-up; CSM, Cervical Spondylotic Myelopathy; JOA, Japanese Orthopaedic Association; NR, Not Reported; ADL, activities of daily living; NSAIDS, non-steroidal anti-
inflammatory drugs; NDI, Neck Disability Index; OPLL, ossification of the posterior longitudinal ligament; RCT, randomized controlled trial  
 
*   N=53; 3 subjects refused conservative treatment 
†   Sx = symptom 
‡   RCT by design; however, data only extracted from conservative arm (prospective cohort) 
§   N=91; n=38 in conservative arm  
** 19 subjects with surgical outcome and 34 with continued conservative treatment; total of 53 subjects remained for final follow-up (83%) 
†† N=101 conservative and surgical arms; 12 subjects in the original conservative arm (n=69) refused treatment
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Table 3. Change in (modified) Japanese Orthopedic Association score following conservative 
treatment in patients with degenerative cervical myelopathy  
 
    JOA* 
Author N F/U (mo) Treatment† Baseline Post Diff 
Kadanka et al 
2002/201133,34 
 
 32 36, 120 
Immobilization 
 
14.6 
 
14.7 0.1 
Li et al 201423 38 30.7 Mixed 14.4 15.5 1.1 
Matsumoto et al 200119  27 47 (12-84) Mixed 13.8 ±1.6 16.1 ±0.9 2.3 
Fukui et al 199022 50 30 Traction 11.1 12.8 1.7 
Shimomura et al 200724  70 35.6 (10-60) Traction 14.6 ±1.3 14.7 ±2.0 0.1 
Kong et al 201328 90 40 (36-56) Traction 14.2 ±1.0 14.2 ±1.3 0 
* 17-point JOA used in all studies except Kadanka et al, who used the 18 point modified JOA 
† See Table 1 for treatment details  
 
 
Table 4. The proportion of patients with degenerative cervical myelopathy requiring surgery following 
conservative treatment.  
 
Author N F/U (mo) Treatment* Baseline JOA n (%) 
Matsumoto et al 200119  27 47 (12-84) Mixed 13.8 ±1.6 10 (37%) 
Fukui et al 199022  50 30 Traction 11.1 27 (54%) 
Kong et al 201328  90 40 (36-56) Traction 14.2 ±1.0 21 (23%) 
Nakamura et al 199820 64 74 (36-129) Mixed NR 19 (30%) 
Yoshimatsu et al 200121 57 29 (1-76) Mixed NR 22 (39%) 
* See Table 1 for treatment details  
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Table 5. GRADE Summary Table 
 
 Number of Studies (N) Strength of Evidence Conclusions 
Clinical Question 1: What is the change in function, pain and quality of life following structured nonoperative treatment? 
mJOA/JOA improvement 
4 prospective cohorts, 
4 retrospective 
cohorts (n=491)    
VERY LOW 
There were no clinical or statistically significant differences 
between mJOA/JOA scores at baseline and follow-up 
following structured nonoperative treatment for DCM. 
Evidence was inconsistent across studies: follow-up time 
ranged from 30 to 74.0 months, baseline mJOA/JOA score 
ranged from 11.1 to 14.6 points, and change in post-
treatment scores ranged from -0.7 to 2.3. One study reported 
improvement in JOA score in 18% of their patient population.   
Clinical Question 2: Does the change in function, pain and quality of life depend on treatment type? 
% of patients with JOA improvement 
 
1 retrospective cohort 
(n=57) 
 
VERY LOW 
1 study reported on the proportion of patients improving by 
≥1 on the JOA score following “rigorous” versus “non-
rigorous” structured nonoperative treatment. The “non-
rigorous” treatment type was not defined. 
Clinical Question 3: Does the change in function, pain and quality of life following nonoperative care differ across subgroups? 
Duration:   
≤ 3 vs. > 3 months 
JOA: ≥ 1 pt. improvement 
< 6 vs. ≥ 6 months 
UE JOA: any improvement 
   LE JOA: any improvement 
1 prospective cohort 
(n=50) 
 
1 retrospective cohort 
(n=61) 
VERY LOW 
≤ 3 mos: 80% 
> 3 mos: 46%   p=.033 
 
< 6 mos: UE: 30%; LE: 36% 
≥ 6 mos: UE: 26%; LE: 23%   p=ns for UE & LE 
Soft disc herniation 
JOA score 
1 retrospective cohort 
(n=27) 
VERY LOW 63% improved  
Clinical Question 4: What are the negative patient outcomes and harms? 
Surgery following nonoperative care  
2 prospective cohorts, 
3 retrospective 
cohorts (n=288) 
 
VERY LOW 
5 studies reported proportion of subjects converting to 
surgery following a period of structured nonoperative 
treatment. 23-54% of patients received surgery following 
structured nonoperative treatment in mostly mild to 
moderate DCM cases. 
 
Page 1 of 35 
 
References  
 
  
1. Kalsi-Ryan S, Karadimas SK, Fehlings MG. Cervical spondylotic myelopathy: the clinical 
phenomenon and the current pathobiology of an increasingly prevalent and devastating 
disorder. The Neuroscientist : a review journal bringing neurobiology, neurology and 
psychiatry. 2013;19(4):409-421. 
2. Tracy JA, Bartleson JD. Cervical spondylotic myelopathy. The neurologist. 
2010;16(3):176-187. 
3. Nouri A, Tetreault L, Singh A, Karadimas SK, Fehlings MG. Degenerative Cervical 
Myelopathy: Epidemiology, Genetics, and Pathogenesis. Spine. 2015;40(12):E675-693. 
4. Lees F, Turner JW. Natural History and Prognosis of Cervical Spondylosis. British 
medical journal. 1963;2(5373):1607-1610. 
5. Nurick S. The natural history and the results of surgical treatment of the spinal cord 
disorder associated with cervical spondylosis. Brain : a journal of neurology. 
1972;95(1):101-108. 
6. Matz PG, Anderson PA, Holly LT, et al. The natural history of cervical spondylotic 
myelopathy. Journal of neurosurgery. Spine. 2009;11(2):104-111. 
7. Karadimas SK, Erwin WM, Ely CG, Dettori JR, Fehlings MG. Pathophysiology and 
natural history of cervical spondylotic myelopathy. Spine. 2013;38(22 Suppl 1):S21-36. 
8. Fehlings MG, Wilson JR, Kopjar B, et al. Efficacy and safety of surgical decompression 
in patients with cervical spondylotic myelopathy: results of the AOSpine North America 
prospective multi-center study. The Journal of bone and joint surgery. American volume. 
2013;95(18):1651-1658. 
9. Fehlings MG, Ibrahim A, Tetreault L, et al. A Global Perspective on the Outcomes of 
Surgical Decompression in Patients with Cervical Spondylotic Myelopathy: Results from 
the Prospective Multicenter AOSpine International Study on 479 patients. Spine. 2015. 
10. Cheung WY, Arvinte D, Wong YW, Luk KD, Cheung KM. Neurological recovery after 
surgical decompression in patients with cervical spondylotic myelopathy - a prospective 
study. International orthopaedics. 2008;32(2):273-278. 
Page 2 of 35 
 
11. Gok B, Sciubba DM, McLoughlin GS, et al. Surgical treatment of cervical spondylotic 
myelopathy with anterior compression: a review of 67 cases. Journal of neurosurgery. 
Spine. 2008;9(2):152-157. 
12. Chiles BW, 3rd, Leonard MA, Choudhri HF, Cooper PR. Cervical spondylotic 
myelopathy: patterns of neurological deficit and recovery after anterior cervical 
decompression. Neurosurgery. 1999;44(4):762-769; discussion 769-770. 
13. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-
Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 
14. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of 
recommendations. BMJ (Clinical research ed.). 2004;328(7454):1490. 
15. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality 
of evidence. Journal of clinical epidemiology. 2011;64(4):401-406. 
16. Kato S, Oshima Y, Oka H, et al. Comparison of the Japanese Orthopaedic Association 
(JOA) Score and Modified JOA (mJOA) Score for the Assessment of Cervical 
Myelopathy: A Multicenter Observational Study. PloS one. 2015;10(4):e0123022. 
17. Furlan JC, Kalsi-Ryan S, Kailaya-Vasan A, Massicotte EM, Fehlings MG. Functional and 
clinical outcomes following surgical treatment in patients with cervical spondylotic 
myelopathy: a prospective study of 81 cases. Journal of neurosurgery. Spine. 
2011;14(3):348-355. 
18. Tetreault L, Kopjar B, Cote P, Nouri A, Fehlings M. The Minimum Clinically Important 
Difference of the modified Japanese Orthopedic Association Scale in Patients with 
Degenerative Cervical Myelopathy. Spine. 
19. Matsumoto M, Chiba K, Ishikawa M, Maruiwa H, Fujimura Y, Toyama Y. Relationships 
between outcomes of conservative treatment and magnetic resonance imaging findings in 
patients with mild cervical myelopathy caused by soft disc herniations. Spine (Phila Pa 
1976). 2001;26(14):1592-1598. 
20. Nakamura K, Kurokawa T, Hoshino Y, Saita K, Takeshita K, Kawaguchi H. Conservative 
treatment for cervical spondylotic myelopathy: achievement and sustainability of a level 
of "no disability". J Spinal Disord. 1998;11(2):175-179. 
Page 3 of 35 
 
21. Yoshimatsu H, Nagata K, Goto H, et al. Conservative treatment for cervical spondylotic 
myelopathy. prediction of treatment effects by multivariate analysis. The spine journal : 
official journal of the North American Spine Society. 2001;1(4):269-273. 
22. Fukui K, Kataoka O, Sho T, Sumi M. Pathomechanism, pathogenesis, and results of 
treatment in cervical spondylotic myelopathy caused by dynamic canal stenosis. Spine. 
1990;15(11):1148-1152. 
23. Li FN, Li ZH, Huang X, et al. The treatment of mild cervical spondylotic myelopathy with 
increased signal intensity on T2-weighted magnetic resonance imaging. Spinal cord. 
2014;52(5):348-353. 
24. Shimomura T, Sumi M, Nishida K, et al. Prognostic factors for deterioration of patients 
with cervical spondylotic myelopathy after nonsurgical treatment. Spine. 
2007;32(22):2474-2479. 
25. Sumi M, Miyamoto H, Suzuki T, Kaneyama S, Kanatani T, Uno K. Prospective cohort 
study of mild cervical spondylotic myelopathy without surgical treatment. Journal of 
neurosurgery. Spine. 2012;16(1):8-14. 
26. Barnes MP, Saunders M. The effect of cervical mobility on the natural history of cervical 
spondylotic myelopathy. Journal of neurology, neurosurgery, and psychiatry. 
1984;47(1):17-20. 
27. Oshima Y, Seichi A, Takeshita K, et al. Natural course and prognostic factors in patients 
with mild cervical spondylotic myelopathy with increased signal intensity on T2-weighted 
magnetic resonance imaging. Spine. 2012;37(22):1909-1913. 
28. Kong LD, Meng LC, Wang LF, Shen Y, Wang P, Shang ZK. Evaluation of conservative 
treatment and timing of surgical intervention for mild forms of cervical spondylotic 
myelopathy. Experimental and Therapeutic Medicine. 2013;6(3):852-856. 
29. Tetreault LA, Kopjar B, Vaccaro A, et al. A clinical prediction model to determine 
outcomes in patients with cervical spondylotic myelopathy undergoing surgical treatment: 
data from the prospective, multi-center AOSpine North America study. The Journal of 
bone and joint surgery. American volume. 2013;95(18):1659-1666. 
30. Tetreault LA, Karpova A, Fehlings MG. Predictors of outcome in patients with 
degenerative cervical spondylotic myelopathy undergoing surgical treatment: results of a 
systematic review. European spine journal : official publication of the European Spine 
Page 4 of 35 
 
Society, the European Spinal Deformity Society, and the European Section of the Cervical 
Spine Research Society. 2015;24 Suppl 2:236-251. 
31. Rhee JM, Shamji MF, Erwin WM, et al. Nonoperative management of cervical 
myelopathy: a systematic review. Spine. 2013;38(22 Suppl 1):S55-67. 
32. Wu JC, Ko CC, Yen YS, et al. Epidemiology of cervical spondylotic myelopathy and its 
risk of causing spinal cord injury: a national cohort study. Neurosurgical focus. 
2013;35(1):E10. 
33. Kadanka Z, Bednarik J, Novotny O, Urbanek I, Dusek L. Cervical spondylotic 
myelopathy: conservative versus surgical treatment after 10 years. Eur Spine J. 
2011;20(9):1533-1538. 
34. Kadanka Z, Mares M, Bednanik J, et al. Approaches to spondylotic cervical myelopathy: 
conservative versus surgical results in a 3-year follow-up study. Spine. 2002;27(20):2205-
2210; discussion 2210-2201. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Electronic (SE) Material 
 
Page 5 of 35 
 
SE Table A. Excluded Studies 
Author   Year  Reason for exclusion 
Arnasson, O.  1987  Myelopathy group treated with surgery only 
Boyce, R.H.  2003  Review article 
Braakman, R.  1994  Review article  
Browder, D.A.  2004  Small sample (n=7); 2 subjects with trauma 
Endo, S.   1994 All trauma subjects 
Fehlings, M.G.  2013 Consensus statement 
Kadanka, Z.  2000 Duplicate of included study (2011) 
Kadanka, Z.  2005 Duplicate of 2011 data 
Law, M.D.  1995  Review article 
Matsunaga, S.   2004  No description of intervention 
Matz, P.G.  2006  Review article 
Mazanec, D.  2007  Inclusion of radiculopathy 
Mochizuki, M.  2009  No description of intervention 
Sahin, N.  2013 Abstract only 
Sampath, P.  2000 Did not report outcomes of interest 
Sanders, M.  1988 Analysis of lumbar condition 
Sumi, M.   2012 Duplicate sample population (Shimomura,T.) 
Wang, G.Q.  2014 Abstract only 
Wang, Y.L.  1997  Not in English 
Wu, J.C.                                   2012  Did not report outcomes of interest 
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SE Table B. Data Summary Table 
Author Follow-up 
(months) 
Follow-up 
(%) 
Pre-treatment score 
± SD /range ( ) 
Post-treatment score Baseline Characteristics 
Fukui, K et al 
(1990) 
30* NR 11.1 (NR) 12.8 (NR) N=50  
Mean age= 58.6 years 
Male= 79%  
Kadanka, Z. et al 
(2002;2011) 
0 
6 
12 
24 
36 
120 
100 
NR 
NR 
NR 
83 
78 
14.6 (14.1-15.2) † 
            -- 
 
14.9 (14.3-15.6) 
15.0 (14.4-15.6) 
14.6 (14.1-15.2) 
14.7 (14.0-15.3) 
15‡ (12.2 -18.0) 
N=35  
Mean age= 54  
Male=74.3%  
Kong, L. et al 
(2013) 
40* 87 Surgical §: 14.0 ±1.1 
Conservative: 14.2 ±1.0 
Surgical: 11.1 ±0.8 
Conservative: 14.2 ±1.3 
N=90 
Mean age= 57.8 years 
Male= 58%  
Li, F.N. et al  
(2014) 
30.7* NR 14.37  15.45 N=38 
Mean age= 51.7 years 
Male= 52%  
Matsumoto, M. 
et al 
(2001) 
0 
3 
6 
47* 
NA 13.8 ±1.6 ** 
 
  
14.2 ±1.4 
14.3 ±1.3 
16.1 ±0.9 
N=27 
Mean age= 44.4 years 
Male= 74%  
Shimomura, T. 
et al (2007) 
35.6* 80 14.6 ±1.3 14.7 ±2.0 N= 70 
Mean age= 55.1 years 
Male= 54% 
* Reported value is mean final follow-up time (mo) 
† Modified JOA (mJOA) out of 18.0 points total 
‡ Reported as median JOA score at final follow-up 
§ Both groups underwent the same conservative treatment initially; Surgical group (n=21) assigned to surgical intervention after deterioration of condition (mean 2.9 point reduction in JOA). The 
remaining 19 subjects (conservative group) continued with conservative treatment until final follow-up (mean of 40 months). 
** Two groups combined with weighted mean values  
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Modified Newcastle-Ottawa Scale (NOS)  
0 = Definitely no (high risk of bias)  
1 = Mostly no  
2 = Mostly yes  
3 = Definitely yes (low risk of bias)  
 
 Selection Bias 
Performance 
Bias 
Detection Bias Information Bias  
 
Appropriate and 
representative 
source 
population? 
Adequate 
Sample size? 
Appropriate 
statistical 
methods? 
Little 
missing 
data? 
Explicitly stated 
and appropriate 
outcome 
measurement? 
Objective 
assessment 
of 
outcome? 
Risk of bias 
Fukui et al 1990 2  2  2 0  3  
3 
Moderately Low Risk of 
Bias 
Kadanka et al 
2002, 2011 
3 1 2 1 3 
3 
Moderately Low Risk of 
Bias 
Kong et al 2013 3 3 3 2 3 
3 
Moderately Low Risk of 
Bias 
Li et al 2014 1 1 2 0 3 
3 
Moderately High Risk of 
Bias 
Matsumoto et al 
2001 
2 0 3 0 3 
3 
Moderately High Risk of 
Bias 
Nakamura et al 
1998 
0 3 3 2 3 
3 
Moderately Low Risk of 
Bias 
Shimomura et al 
2007 
2 3 3 2 3 
3 
Moderately Low Risk of 
Bias 
Yoshimatsu et al 
2001 
2 2 3 0 3 
3 
Moderately Low Risk of 
Bias 
 
Domain of evaluation: Methods for selecting study participants (i.e. Selection bias) 
Is the source population (cases, controls, cohorts) appropriate and representative of the population of interest? 
Example of low risk of bias: A consecutive sample or random selection from a population that is representative of the condition under study. 
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Example of moderate risk of bias: A consecutive sample or random selection from a population that is not highly representative of the condition 
under study. 
Example of high risk of bias:  The source population cannot be defined or enumerated (i.e. volunteering or self-recruitment). 
 
Domain of evaluation: Methods to control confounding (i.e. Performance bias) 
Is the sample size adequate and is there sufficient power to detect a meaningful difference in the outcome of interest? 
Example of low risk of bias: Sample size was adequate and there was sufficient power to detect a difference in the outcome. 
Example of high risk of bias: Sample size was small and there was not enough power to test outcome of interest. 
 
Did the study identify and adjust for any variables or confounders that may influence the outcome? 
Example of low risk of bias: The study identified and adjusted for all possible confounders that may influence estimates of association between 
exposure and outcome (i.e. Was the patient being treated for a medical condition such as chronic pain and was being prescribed opioids while 
on methadone treatment?) 
Example of moderate risk of bias: The study identified and reported possible variables that may influence the outcome but did not explore the 
interaction. 
Example of high risk of bias: The study either did not report any variables of influence or acknowledge variables of influence when it was clear 
they were present. 
 
Domain of evaluation: Statistical methods (i.e. Detection bias) 
Did the study use appropriate statistical analysis methods relative to the outcome of interest? 
Example of low risk of bias: The study reported use of appropriate statistical analysis as required (i.e. adjusting for an unbalanced distribution of 
a specific covariate among sexes, or correcting for multiple testing error) 
Example of moderate risk of bias: The study either used correct statistical methods but did not report them well, or used incorrect methods but 
reported them in detail. 
Example of high risk of bias: The study did not use appropriate statistical analysis as required (i.e. did not adjust for an unbalanced distribution of 
a specific covariate among sexes, or correct for multiple testing error when necessary) or did not report them adequately. 
 
Is there little missing data and did the study handle it accordingly? 
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Example of low risk of bias: The study acknowledged missing data to be less than 10% and specified the method used to handle it. 
Example of moderate risk of bias: The study had greater than 15% missing data but specified the method used to handle it. 
Example of high risk of bias: The study had greater than 15% missing data and did not handle it at all. 
 
Domain of evaluation: Methods for measuring outcome variables (i.e. Information bias) 
Is the methodology of the outcome measurement appropriate and explicitly stated? 
Example of low risk of bias: The study provided a detailed description of the outcome measure(s) which are appropriate for the outcome of 
interest. 
Example of moderate risk of bias: The study provided a somewhat complete description of outcome measurements and they are justified. 
Example of high risk of bias: The study provided limited information on the methods of measuring the outcome and the measure is not 
appropriate considering the outcome. 
 
Is there an objective assessment of the outcome of interest? 
Example of low risk of bias: The study used objective methods to discern the outcome of participants (i.e. laboratory measurements, medical 
records). 
Example of moderate risk of bias: The study relied on subjective data as the primary method to discern outcome of participants (i.e. self-report). 
Example of high risk of bias: The study had limited reporting about outcome assessment. 
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SE Table D. GRADE Evaluation Details, Clinical Question 1 
Clinical Question 1: What is the change in function, pain and quality of life  following structured nonoperative treatment? Effect Size 
Outcome Sample Size Risk of 
bias 
Inconsistency Indirectness Imprecision Publication 
bias 
Overall quality of 
evidence 
% or mean 
difference 
(MD) 
 
 
 
mJOA/JOA 
improvement 
1 prospective 
cohort (n=50)* 
 
Serious 
risk of 
bias† 
Inconsistency 
unknown 
No serious 
indirectness 
Serious risk of 
imprecision 
Undetected INSUFFICIENT MD: 1.7  
3 prospective 
cohorts 
(n=195) 
 
Serious 
risk of 
bias† 
Serious risk of 
inconsistency‡ 
No serious 
indirectness 
No serious risk 
of imprecision 
Undetected INSUFFICIENT§ Range of MDs: 
0 to 0.1 
3 retrospective 
cohorts 
(n=129) 
Serious 
risk of 
bias† 
Serious risk of 
inconsistency‡ 
No serious 
indirectness 
Serious risk of 
imprecision 
 
Undetected INSUFFICIENT§ Range of MDs: 
1.1 to 2.3 
 
% patients with 
JOA 
improvement** 
 
1 retrospective 
cohort (n=57) 
 
Serious 
risk of 
bias† 
Inconsistency 
unknown 
No serious 
indirectness 
Serious risk of 
imprecision 
Undetected  INSUFFICIENT 18% (15/57)  
*   One study using mJOA scale  
†  Serious risk of bias: the majority of studies did not meet two or more important criteria of a good quality RCT or cohort  
‡   Serious inconsistency: point estimates vary across studies in such a way that affects the confidence of the effect estimate 
§   Downgraded 1 due to risk of bias and 1 for inconsistency 
** Threshold for JOA improvement not defined 
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SE Table E: GRADE Evaluation Details, Clinical Question 2 
Clinical Question 2: Does the change in function, pain and quality of life vary depending on treatment type? Treatment groups Effect 
Size 
 
Outcome 
 
Sample Size 
Risk of 
bias 
Inconsistency Indirectness Imprecision Publication 
bias 
Overall 
quality of 
evidence 
Rigorous 
(%) 
Nonrigorous 
(%) 
Relative 
Risk 
 
% patients 
with JOA 
improvement‡ 
 
 
1 
retrospective 
cohort 
(n=57) 
 
 
Serious 
risk of 
bias* 
 
Inconsistency 
unknown 
 
No serious 
indirectness 
 
Serious risk 
of 
imprecision 
 
Undetected 
 
INSUFFICIENT 
 
38 
(14/37) 
 
6 (2/32) 
 
6.1 
(95% CI 
1.5, 
24.6) 
* Serious risk of bias: the majority of studies did not meet two or more important criteria of a good quality RCT or cohort  
† Serious inconsistency: point estimates vary across studies in such a way that affects the confidence of the effect estimate 
‡ Threshold for JOA improvement not defined 
 
SE Table F. GRADE Evaluation Details, Clinical Question 4 
* Serious risk of bias: the majority of studies did not meet two or more important criteria of a good quality RCT or cohort  
† Serious inconsistency: point estimates vary across studies in such a way that affects the confidence of the effect estimate 
‡ Downgraded 1 due to risk of bias and 1 for inconsistency 
Clinical Question 4: What are the negative patient outcomes and harms? Effect Size 
Outcome Sample Size Risk of 
bias 
Inconsistency Indirectness Imprecision Publication 
bias 
Overall quality 
of evidence 
% difference 
 
 
Surgery 
following 
nonoperative 
care 
 
2 prospective 
cohorts, 3 
retrospective 
cohorts 
(n=288) 
 
 
Serious 
risk of 
bias* 
 
Serious risk of 
inconsistency† 
 
No serious 
indirectness 
 
Serious risk of 
imprecision 
 
Undetected 
 
INSUFFICIENT‡ 
 
Range: 23 – 54% 
